Harvard Bioscience Inc
HBIO- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001123494
No open-market purchases or sales by Harvard Bioscience Inc insiders were filed in the last 90 days; 37 institutions reported holding it in 13F filings for Q2 2026, worth $10.3M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Harvard Bioscience Inc as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 95
- −4 vs. Q2 2024
- Shares held
- 31.3M
- +2.33M (+8.0%) vs. Q2 2024
- Total value
- $84.2M
- +$1.61M (+2.0%) vs. Q2 2024
- New holders
- 14
- 32 more added
- Sold out
- 18
- 27 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 37 | $10.3M |
| Q1 2026 | 37 | $7.73M |
| Q4 2025 | 64 | $11.7M |
| Q3 2025 | 61 | $7.29M |
| Q2 2025 | 69 | $8.39M |
| Q1 2025 | 92 | $14.5M |
| Q4 2024 | 96 | $65.5M |
| Q3 2024 | 95 | $84.2M |
| Q2 2024 | 100 | $90.7M |
| Q1 2024 | 90 | $137.8M |
| Q4 2023 | 93 | $176.4M |
| Q3 2023 | 94 | $141.6M |
| Q2 2023 | 100 | $178.2M |
| Q1 2023 | 66 | $127.2M |
| Q4 2022 | 68 | $83.3M |
| Q3 2022 | 79 | $74.0M |
| Q2 2022 | 91 | $106.8M |
| Q1 2022 | 98 | $187.3M |
| Q4 2021 | 103 | $211.4M |
| Q3 2021 | 99 | $191.7M |
| Q2 2021 | 99 | $232.3M |
| Q1 2021 | 87 | $144.2M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Harvard Bioscience Inc; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of Montreal | 0 | $0 | 0.00% | −28,404−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −20,200−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −19,647−100.0% | Sold out |
| Gamco Investors, Inc. Et Al | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −14,143−100.0% | Sold out |
| Petrus Trust Company, LTA | 0 | $0 | 0.00% | −13,798−100.0% | Sold out |
| Portolan Capital Management, LLC | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −10,015−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −2,428−100.0% | Sold out |
| Innealta Capital, LLC | 0 | $0 | 0.00% | −1,671−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −1,664−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −310−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −56−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |